Patent

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Retrieved on: 
Monday, March 25, 2024
Orphan drug, Primary sclerosing cholangitis, Inflammation, Fast Track, European Patent Organisation, Antibody, PSC, Liver, Liver transplantation, Doctor of Philosophy, CCL24, Fibrosis, Treatment, Therapy, European Patent Convention, CMMB, Patent, Use, Hepatology, FDA, TEL, Pharmaceutical industry

TEL AVIV, Israel, March 25, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today reported that the European Patent Office has granted a new patent for CM-101, Chemomab’s first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive fibrosis and inflammation. CM-101 is currently being assessed in the global Phase 2 SPRING trial for the treatment of primary sclerosing cholangitis (PSC). Patient enrollment in the trial has been completed, with a topline data readout expected midyear 2024.

Key Points: 
  • CM-101 is currently being assessed in the global Phase 2 SPRING trial for the treatment of primary sclerosing cholangitis (PSC).
  • Patient enrollment in the trial has been completed, with a topline data readout expected midyear 2024.
  • The new European patent covers the use of CM-101 and sequence-related anti-CCL24 antibodies for the treatment of hepatic (liver) diseases, including PSC.
  • Unlike other drugs in development for PSC, CM-101 has a unique dual mechanism of action that simultaneously blocks fibrosis and inflammation.

AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results

Retrieved on: 
Friday, March 22, 2024
Research, Separation, Biotechnology, Regeneration, AgeX Therapeutics, Finance, Exchange, Accounting standard, Insurance, Bank statement, ASC, Therapy, Patent, Private law, Consultant, Ageing

ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2023 and recent highlights.

Key Points: 
  • ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2023 and recent highlights.
  • The Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of AgeX common stock on February 1, 2024.
  • As of December 31, 2023, AgeX owed Juvenescence Limited $4.5 million in principal and origination fees on account of loans extended to AgeX.
  • Operating expenses for the full year 2023 were $10.1 million as compared with $7.0 million in the same period of 2022.

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Friday, March 22, 2024
Research, CKPT, FASN, Exercise, Biologics license application, Patent, Safety, Immunotherapy, Patient, FACP, Journal, CRL, Society, Nephrology, JITC, File, Marketing, FDA, Hematology, BLA, Alexion

WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights.

Key Points: 
  • WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights.
  • We look forward to providing additional updates in the second quarter.”
    2023 and Recent Corporate Highlights:
    Checkpoint submitted a BLA to the FDA seeking approval of cosibelimab in January 2023 and the FDA accepted the BLA for filing in March 2023.
  • In December 2023, Checkpoint announced that the U.S. Patent and Trademark Office (“USPTO”) issued a new patent (U.S. Patent No.
  • In July 2023, Checkpoint announced new, longer-term data for cosibelimab from its pivotal studies in locally advanced and metastatic cSCC.

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Retrieved on: 
Friday, March 22, 2024
MYGN, Diagnosis, Genetic testing, Patent, Combinatorics, Genetics, Patient, Neoplasm, Research, DNA, Myriad Genetics, Doctor of Philosophy, Oncology, Medicine, University, MD Anderson Cancer Center, MRD, Intellectual property, FDA, Estate (law), Pharmaceutical industry

U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA.

Key Points: 
  • U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA.
  • This method describes a key aspect of tumor-informed MRD assays that detect circulating tumor DNA (ctDNA) through sequencing.
  • Specifically, the patented method relates to the manner in which a sample is sufficiently enriched with ctDNA that it can be detected, if present, with high sensitivity and specificity.
  • “The 2016 filing date of this patent—at the advent of MRD development—highlights Myriad’s foresight about the potential role of tumor-derived cell-free DNA in the expanding field of cancer diagnostics,” said Paul J. Diaz, President and CEO, Myriad Genetics.

Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update

Retrieved on: 
Friday, March 22, 2024
Diagnosis, Research, U.S. FDA, Peripheral artery disease, Infection, Patent, Buddha's hand, Evaluation, PAD, Journal, Sale, University, Doctor of Philosophy, Efficacy, Priority review, Regenerative medicine, Clinical trial, Trial of the century, Vascular surgery, HAV, Hospital, Injury, Nationwide Children's Hospital, HUMA, FACS, Amputation, Food, FDA, Defense, BLA, PDUFA, Pharmaceutical industry

DURHAM, N.C., March 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced financial results for the fourth quarter and year ended December 31, 2023 and highlighted recent corporate accomplishments in advancing the investigational Human Acellular Vessel (HAV) closer to planned U.S. market launch.

Key Points: 
  • There was no revenue for either the fourth quarter of 2023 or the fourth quarter of 2022, and there was no revenue for the year ended December 31, 2023.
  • Research and development expenses were $20.2 million for the fourth quarter of 2023, compared to $15.0 million for the fourth quarter of 2022, and were $76.6 million for the year ended December 31, 2023, compared to $63.3 million for the year ended December 31, 2022.
  • General and administrative expenses were $6.0 million for the fourth quarter of 2023, compared to $5.8 million for the fourth quarter of 2022, and were $23.5 million for the year ended December 31, 2023, compared to $22.9 million for the year ended December 31, 2022.
  • The 2023 increases in net loss resulted from the non-cash remeasurement of the contingent earnout liability, and operating expense increases, described above.

Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria

Retrieved on: 
Friday, March 22, 2024
Brain, Taste, Nitisinone, Partnership, Education, Patient, PKU, Phenylalanine, DSM-IV codes, Insurance, Protein, APR, Diet, Homocystinuria, Patent, OTCQB, FDA, Practitioner, Pharmaceutical industry

After extensive discussions with metabolic geneticists, dieticians, and PKU patients, we believe PKU GOLIKE is the best product in the estimated $100 million U.S. PKU medical formula market.

Key Points: 
  • After extensive discussions with metabolic geneticists, dieticians, and PKU patients, we believe PKU GOLIKE is the best product in the estimated $100 million U.S. PKU medical formula market.
  • PKU GOLIKE’s taste-masked, odor-free coating technology is designed to provide a better taste and a superior experience compared to alternative PKU medical formulas.
  • Relief launched PKU GOLIKE Granules in the United States in the fourth quarter of 2022 and the PKU GOLIKE Tropical Bar in the second quarter of 2023.
  • Eton plans to promote PKU GOLIKE with its existing metabolic sales force, which currently promotes Eton’s Carglumic Acid, Betaine, and Nitisinone products.

ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 21, 2024
Research, Nitrosamine, Anaphylaxis, Symantec Endpoint Protection, Absorption, Human, ARS, MAA, Patent, Caregiver, PD, New Drug Application, SAN, Patient, Adrenaline, Journal, CRL, NDA, American Academy, EMA, Quality of life, Trial of the century, Flare, American College, Investment, Clinical trial, Erythema, Lower respiratory tract infection, Asthma, Body surface area, Itch, Allergy, FDA, AAAAI, Total, Food, Pharmaceutical industry

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today reported business updates and financial results for the fourth quarter and full year 2023.

Key Points: 
  • In February 2024, ARS Pharma announced the successful completion of the repeat dosing study of neffy in seasonal allergic rhinitis under nasal allergen challenge conditions.
  • R&D Expenses: Research and development expenses were $3.4 million and $20.3 million for the quarter and year ended December 31, 2023, respectively.
  • G&A Expenses: General and administrative expenses were $6.8 million and $47.3 million for the quarter and year ended December 31, 2023, respectively.
  • Net Loss: Net loss was $7.2 million and $54.4 million for the quarter and year ended December 31, 2023, respectively.

Nano Dimension Announces Record 2023 Revenue of $56.3 Million and Organic Growth of 29%

Retrieved on: 
Thursday, March 21, 2024
Research, Service provider, Attention, ROI, Senior, RET, Tower Semiconductor, Initiative, AME, Share repurchase, Sale, 3D, Acquisition, G&A, Aviation, Multi, ADS, Record, Nano, Robotics, Annual general meeting, PCB, Vice president, Workforce, Patent, 3D printing, Fraunhofer Society, Marketing, Corporate development, Human, Army, Printing, Video game

WALTHAM, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM, “Nano Dimension” or the “Company”), a leading supplier of Additively Manufactured Electronics (“AME”) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (“AM”), today announced financial results for the fourth quarter and full year ended December 31st, 2023.

Key Points: 
  • Nano Dimension has a breadth of technologies and products assortment, yet narrow and focused span of synergistic vertical markets.
  • It is specifically designed to enable Nano Dimension to become operating income positive in 2025, and potentially cash flow positive earlier.
  • As an example, Q4/2023’s $14.5 million in revenue was 19% higher than the same period in the year before.
  • With close to $56.3 million of revenue, Nano Dimension is the fastest growing of the cohort of publicly traded AM / 3D printing companies (approximately 10-12).

Novarad Wins Patent Litigation with Medivis Over Augmented Reality Navigation System

Retrieved on: 
Wednesday, March 20, 2024
Anatomy, VISAR, 3D, PTAB, Surgeon, Patent, Data, FDA, Physician, Medicine

Salt Lake City, Utah, March 20, 2024 (GLOBE NEWSWIRE) -- Novarad Corporation, a leading provider of augmented reality surgical navigation, is thrilled to announce a significant legal victory in a recent patent case.

Key Points: 
  • Salt Lake City, Utah, March 20, 2024 (GLOBE NEWSWIRE) -- Novarad Corporation, a leading provider of augmented reality surgical navigation, is thrilled to announce a significant legal victory in a recent patent case.
  • The decision, reached in Novarad Corp. v. Medivis, Inc., is poised to have far-reaching consequences for Novarad and its groundbreaking augmented reality product, VisAR.
  • In the case of Novarad Corp. v. Medivis, Inc., the Patent Trial and Appeal Board (PTAB) rendered a decision in favor of Novarad; dismissing a petition to invalidate Novarad’s patent.
  • "With this legal victory behind us, we are more determined than ever to continue advancing the frontiers of augmented reality technology in medicine."

Fujifilm Files Patent Infringement Lawsuit Against Eastman Kodak Company

Retrieved on: 
Wednesday, March 20, 2024
Fujifilm, Patent, Kodak, District court, KODK, Research, Sale, Unified Patent Court, Investment, 3D printing

HANOVER PARK, Ill., March 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM North America Corporation, Graphic Communication Division today announced that FUJIFILM Corporation filed a patent infringement lawsuit against Eastman Kodak Company (NYSE: KODK) in the United States District Court for the District of New Jersey.

Key Points: 
  • HANOVER PARK, Ill., March 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM North America Corporation, Graphic Communication Division today announced that FUJIFILM Corporation filed a patent infringement lawsuit against Eastman Kodak Company (NYSE: KODK) in the United States District Court for the District of New Jersey.
  • Fujifilm has asserted four patents (U.S. Patent Nos.
  • 10,427,443, 10,525,696, 10,875,346, and 11,294,279) pertaining to various aspects of processless lithographic printing plate technologies, including method and apparatus claims.
  • “We will enforce and protect our innovation and intellectual property rights in the United States and around the world when we believe others infringe unfairly.”
    Separately in October 2023 and December 2023 respectively, Eastman Kodak’s European subsidiaries, Kodak GmbH, Kodak Graphic Communications GmbH, and Kodak Holding GmbH, were sued by FUJIFILM Corporation for infringement of the related European counterparts of the US patents-in-suit in the Unified Patent Court and in Germany.